Biosimilars: Infliximab IV, Tocilizumab IV en SC, Denosumab SC en Epoëtine alfa
TED · 763149-2026Contract noticeCloses in 26 days · 2026-12-01
Value
Estimated—
Awarded—
CPV codes
33690000 Medical equipment & pharmaceuticalsDescription
Biosimilars: Infliximab IV, Tocilizumab IV en SC, Denosumab SC en Epoëtine alfa
Similar tenders
Closest by meaning — across languages, via embeddings.
| Published | Title | Buyer | Match |
|---|---|---|---|
| 2026-09-11 | infliximab IV - tocilizumab IV en SC - natalizumab IV - denosumab SC | EMMAUS VZW BE | 95% |
| 2026-10-28 | TOCILIZUMAB SOL INJ - ROCHE - BIOSSIMILARES | Unidade Local de Saúde de Coimbra, EPE PT | 91% |
| 2026-09-16 | Spécialités pharmaceutiques à base d'infliximab IV | — BE | 89% |
| 2026-05-05 | 261G000469 - INFLIximab 100 MG INJ BIOSSIMILAR (ZESSLY) | Unidade Local de Saúde Santa Maria, E.P.E. PT | 89% |
| 2026-05-19 | Suministro de Infliximab (DOE), Ustekinumab (DOE) y Bevacizumab (DOE) | OSAKIDETZA - Servicio Vasco de Salud - Organización Central ES | 89% |
| 2026-09-07 | Suministro de Tocilizumab (DOE) | OSAKIDETZA - Servicio Vasco de Salud - Organización Central ES | 89% |